NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NA
Post# of 1861
(Total Views: 222)
Posted On: 08/03/2023 4:01:46 PM
NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports on Berubicin Pivotal Study, Announces Participation in Biotech Conference
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, released an update on its ongoing clinical study evaluating Berubicin for the treatment of recurrent GBM, an aggressive and incurable form of brain cancer. According to the report, the company continues to see rapid progression and acceleration of enrollment for the study, with 180 patients of the 243 expected currently enrolled across 46 clinical trial sites. In addition, CNS has documented the necessary number of patients reaching the primary efficacy endpoint, or overall survival, to conduct preplanned interim analysis. Topline data from the interim analysis should be available by the end of this year, which is also when the company expects the study will conclude. “Enrolling patients in an orphan disease trial is always a challenge, and that’s why we are thrilled with the rate of enrollment in this potentially pivotal study,” said CNS Pharmaceuticals CEO John Climaco in the press release. “The robust interest and enthusiasm among our investigators and patients reflect the pressing need to develop treatment options for patients with GBM. Addressing this devastating disease continues to be the driving force for our team.”
In addition, the company announced that Climaco will be featured in a live, moderated fireside chat on Benzinga’s upcoming Virtual Biotech Conference. The conference is slated for Aug. 3, 2023; the fireside chat will begin at 11:35 a.m. ET. Benzinga’s Virtual Biotech Conference spotlights biotech leaders and features the hottest companies in the biotech space today.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, released an update on its ongoing clinical study evaluating Berubicin for the treatment of recurrent GBM, an aggressive and incurable form of brain cancer. According to the report, the company continues to see rapid progression and acceleration of enrollment for the study, with 180 patients of the 243 expected currently enrolled across 46 clinical trial sites. In addition, CNS has documented the necessary number of patients reaching the primary efficacy endpoint, or overall survival, to conduct preplanned interim analysis. Topline data from the interim analysis should be available by the end of this year, which is also when the company expects the study will conclude. “Enrolling patients in an orphan disease trial is always a challenge, and that’s why we are thrilled with the rate of enrollment in this potentially pivotal study,” said CNS Pharmaceuticals CEO John Climaco in the press release. “The robust interest and enthusiasm among our investigators and patients reflect the pressing need to develop treatment options for patients with GBM. Addressing this devastating disease continues to be the driving force for our team.”
In addition, the company announced that Climaco will be featured in a live, moderated fireside chat on Benzinga’s upcoming Virtual Biotech Conference. The conference is slated for Aug. 3, 2023; the fireside chat will begin at 11:35 a.m. ET. Benzinga’s Virtual Biotech Conference spotlights biotech leaders and features the hottest companies in the biotech space today.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)